IntoCell

IntoCell Debt

The Debt of IntoCell (287840.KQ) as of Oct 15, 2026 is 10.00 B KRW. In the previous year, Debt was 10.06 B KRW — a change of -0.58% (lower).

Debt

10.00 BKRW

YoY

-0.58%

Last updated:

In 2025, IntoCell's total debt was 10.00 B KRW, a -0.58% change from the 10.06 B KRW total debt recorded in the previous year.

The IntoCell Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2023
10.02 B KRW
Jan 1, 2024
10.06 B KRW
Jan 1, 2025
10.00 B KRW
The IntoCell Debt history
YEARDebtYoY
10.00 BKRW-0.58%
10.06 BKRW+0.43%
10.02 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IntoCell Stock analysis

What does IntoCell do? IntoCell Inc is a biotechnology company based in Daejeon, South Korea, operating within the Health Care sector. The company has 43 full-time employees and is engaged in the research and development of advanced drug delivery technologies. IntoCell's primary focus is on the development of ADC (Antibody-Drug Conjugate) platform technology, with a specific emphasis on its ortho-hydroxy-protected aryl sulfate (OHPAS) platform. This OHPAS technology serves as a linker that connects therapeutic drugs to antibodies. Additionally, the company is developing payload modification technology (PMT), designed to minimize drug uptake into healthy cells, thereby improving targeted drug delivery. IntoCell also works on proprietary drug technologies relevant to ADC development. The company completed its initial public offering (IPO) on May 23, 2025, marking a significant milestone in its corporate development. Its headquarters are located in Daejeon, a city known for its strong presence in South Korea's biotechnology and research sectors. The company's website is http://intocell.co.kr/, where further information about its technologies and corporate activities can be found. As a relatively new entrant to the public market, IntoCell Inc is positioned to contribute to advancements in targeted cancer therapies through its innovative platform technologies. IntoCell is one of the most popular companies on Eulerpool.

Debt Details

Understanding IntoCell's Debt Structure

IntoCell's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing IntoCell's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to IntoCell’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in IntoCell’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about IntoCell stock

Debt of IntoCell is 10.00 B KRW in 2025.

Debt of IntoCell changed from 10.06 B KRW to 10.00 B KRW, representing a -0.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt IntoCell since 2006 – with annual values, charts, and detailed analysis.

Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's IntoCell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — IntoCell

All Key Metrics — IntoCell